1.Measured by its binding ability in a functional ELISA. Immobilized Human TIGIT His, Biotinylated at 2 μg/ml (100 μl/well) can bind Mouse CD155/PVR His & hFc , the EC50 of Mouse CD155/PVR His & hFc is 50-250 ng/mL. 2. Using the Octet RED System, the affinity constant (Kd) of TIGIT Protein, Human, Recombinant (His Tag), Biotinylated bound to MITG7192A was 0.1 nM.

TIGIT Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 14.2 kDa and the accession number is Q495A1-1.

Human

HEK293 Cells

WUCAM,VSTM3,VSIG9,T cell immunoreceptor with Ig and ITIM domains

A DNA sequence encoding the TIGIT (NP_776160.2) (Met1-Phe138) was expressed with a C-terminal polyhistidine tag. The purified protein was biotinylated in vitro. Predicted N terminal: Met 22

> 90 % as determined by SDS-PAGE.

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy